Current Report · Items 2.02, 9.01 · 8-K

Haemonetics Corporation

HAENYSEEQUITYCurrent

Results of Operations and Financial Condition

Filed May 7, 2026Accepted May 7, 2026, 6:02 AM EDTCIK 313143Accession 0000313143-26-000031

Company context

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.

Current securities

HAENYSE · EQUITY · Current

Recent company filings

Registered securities in this filing

HAEMONETICS CORPORATION · 8-K · Filed 2026-05-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, $.01 par value per share

Symbol: HAE
Exchange: NYSE
Classification: COMMON
Status: Current

Filing context

Context: c-1

Dimensions: Not supplied

Accession 000031314326000031 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Filed exhibits (1)

EX-99.1 (by filename) ex991-q4mar2026earningsrel.htm

Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director- Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Fourth Quarter and Fiscal 2026 Results; Provides Fiscal 2027 Guidance Boston, MA, May 7, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2026, which ended March 28, 2026: Fourth Quarter Fiscal 2026 Fiscal 2026 ─────────────────────────────────────────────────────────────────────────────────────────────────────────── n Revenue, increase/(decrease) $346 million, 4.8% $1.334 billion, (2.0)% n Organic(1) revenue increase 4.5% …

Open exhibit ↗

Get the free weekly BCS email.